PMS & PMDD
Premenstrual symptoms are common — and PMDD is not 'bad PMS' but a severe, treatable mood disorder
What it is
Most people who menstruate notice something in the days before a period — bloating, breast tenderness, irritability, low mood — and when those symptoms are mild and predictable, that is premenstrual syndrome (PMS). Premenstrual dysphoric disorder (PMDD) is a different thing in degree and in kind: a severe, cyclical mood disorder, recognised as a formal psychiatric diagnosis, in which the week or so before a period brings marked irritability, depression, anxiety or mood swings severe enough to damage relationships, work and daily life — and which lifts within a few days of the period starting. The defining feature of both is the timing: symptoms appear in the luteal phase (after ovulation) and resolve once menstruation begins. PMDD is not a character flaw, not 'just hormones', and not something to be talked out of. It is a real condition with real treatments.
Why it matters
This page exists to correct an error that cuts both ways. On one side, PMDD is routinely minimised — dismissed as women being over-sensitive, or as ordinary PMS exaggerated — when it is in fact a distinct disorder that affects a small but significant minority (roughly 2 to 5% of menstruating women) and carries a genuinely elevated risk of suicidal thoughts and attempts. Taking it seriously matters. On the other side, the label is often applied loosely: because people naturally overestimate how cyclical their symptoms are, a formal diagnosis requires tracking symptoms prospectively across at least two cycles, and a large share of those who report PMDD do not confirm it when they chart it day by day. The stakes of getting this right are practical: the confirmed diagnosis is very treatable, and mistaking a continuous depression or anxiety disorder for a cyclical one — or vice versa — sends treatment in the wrong direction.
What BioSignal knows about treating this
What works for PMS & PMDD
BioSignal’s clinical summary, most important first.
- SSRIs (such as sertraline, fluoxetine, escitalopram) — first-line for PMDD, effective taken either continuously or only in the luteal phase
- Combined hormonal contraception, particularly drospirenone-containing pills taken with a shortened or no hormone-free interval
- Cognitive behavioural therapy — reasonable, though the evidence base is limited
- Calcium supplementation — the supplement with the most credible randomised evidence
- GnRH agonists, and rarely surgery, reserved for the most severe treatment-resistant cases
- Urgent mental-health support where there are suicidal thoughts
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Antidepressants (SSRIs & SNRIs)High confidence
They beat placebo — the evidence is strong. The average effect is modest and grows with severity. The chemical-imbalance explanation was wrong; the medication still works. Withdrawal is real: taper slowly, never abruptly, with your prescriber.
- Hormonal ContraceptionHigh confidence
Highly effective and safe for most. The decision that matters is METHOD, not whether: typical-use failure differs roughly tenfold between the pill and a coil.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Being of reproductive age and menstruating (symptoms typically resolve at menopause)
- A personal or family history of depression, anxiety, or PMDD
- A history of trauma or significant psychosocial stress
- Smoking
- It is a sensitivity to normal cyclical hormone changes — not abnormal hormone levels
How it's diagnosed
The diagnosis rests on the pattern in time, not on a blood test — hormone levels in PMDD are normal, and the problem is an unusual sensitivity to ordinary cyclical changes. The essential step, and the one most often skipped, is PROSPECTIVE symptom tracking: recording symptoms daily across at least two menstrual cycles (with a validated tool such as the Daily Record of Severity of Problems), rather than relying on memory. This matters because people substantially overestimate how cycle-linked their symptoms are, and many who report PMDD do not meet criteria once they chart prospectively. For a PMDD diagnosis, symptoms must cluster in the final week before menses, start improving within a few days of the period beginning, be minimal in the week after, cause clear functional impairment, and — crucially — not simply be the premenstrual worsening of an underlying depression or anxiety disorder that is present all month.
Key biomarkers
Biomarker pages for this condition are on the roadmap.
Lifestyle
Explore this condition across BioSignal
Related Signal Records
Related conditions
Frequently asked questions
What is the difference between PMS and PMDD?
Severity and character. PMS covers the common, milder physical and emotional symptoms — bloating, tenderness, irritability — that many people get before a period and that do not seriously disrupt life. PMDD is a severe, formally recognised mood disorder: the premenstrual week brings intense irritability, depression, anxiety or mood swings that genuinely impair relationships and functioning, then lift within days of the period starting. The crucial thing is that PMDD is not simply 'worse PMS' to be endured — it is a diagnosable condition with effective treatments, and it affects roughly 2 to 5% of menstruating women. If your premenstrual symptoms are wrecking parts of your life every month, that is worth taking to a clinician rather than tolerating.
How is PMDD actually diagnosed — can't I just tell it's cyclical?
Not reliably from memory, and this is genuinely counterintuitive. People substantially overestimate how tightly their symptoms track the menstrual cycle, so a proper PMDD diagnosis requires prospective daily tracking across at least two cycles — recording symptoms as they happen, not recalling them afterwards. When this is done, a large proportion of women who were sure they had PMDD turn out to have symptoms that are not actually confined to the luteal phase, which usually means an underlying depression or anxiety disorder that gets worse premenstrually rather than PMDD. That distinction is not academic: it changes the treatment. So the single most useful thing you can do before an appointment is start charting your symptoms daily against your cycle.
What treatments actually work for PMDD?
Two have solid evidence. SSRIs (antidepressants such as sertraline or fluoxetine) are first-line and reduce the mood symptoms of PMDD; unusually, they can work when taken only in the luteal phase — the two weeks before a period — not just continuously, which is different from how they are used for depression. Combined hormonal contraceptives, particularly those containing drospirenone taken with a shortened or eliminated pill-free week, also help, though the benefit is modest and the placebo response is large. Beyond these, cognitive behavioural therapy is reasonable but less well evidenced, and calcium is the best-supported supplement. For the most severe, treatment-resistant cases there are stronger hormonal options and, very rarely, surgery. The important message is that effective treatment exists — PMDD is not something you simply have to live with.
Do supplements like chasteberry, evening primrose oil or vitamin B6 help?
The honest answer is: mostly weakly, with one modest exception. Calcium (around 1,200 mg a day) has the most credible randomised evidence, reducing symptoms meaningfully more than placebo in a good trial. Chasteberry (Vitex agnus-castus) shows a positive signal, but the trials behind it are largely low-quality and prone to bias, so the effect is uncertain. Vitamin B6 has weak, low-quality evidence, and high doses (above about 100 mg a day) can actually cause nerve damage, so it is not a 'more is better' supplement. Evening primrose oil is popular but poorly supported for the mood symptoms. None of these is a substitute for proper treatment in genuine PMDD — they sit at the mild end, and the marketing around them runs well ahead of the evidence.
Is it PMDD, or is it depression or anxiety?
The dividing line is the timing. PMDD symptoms are locked to the luteal phase — they arrive in the days before a period and clear within a few days of it starting, leaving a symptom-free stretch each month. Depression and anxiety disorders are not cycle-locked; they persist across the whole month, though they can worsen premenstrually. That premenstrual worsening of an ongoing condition is common — around half of people with premenstrual complaints have a co-existing mood or anxiety disorder — and it is treated differently from true PMDD. This is exactly why prospective tracking matters, and it is also why BioSignal keeps these as separate pages: a cyclical disorder and a continuous one are not the same problem, and answering a depression question with a PMDD page (or the reverse) would be a real error.
I feel suicidal in the days before my period — what should I do?
Please treat that as serious and reach out now — you deserve support with it rather than a page. PMDD carries a genuinely raised risk of suicidal thoughts and attempts, and feeling this way premenstrually is a recognised part of the condition, not a personal failing or something to wait out alone. If you are having thoughts of harming yourself, contact your local emergency number or a crisis line in your country, or reach someone you trust. And because PMDD is treatable, this is worth raising with a doctor as its own priority: the cyclical pattern that makes these days so hard is also what makes them targetable with treatment.
Evidence summary
Premenstrual symptoms are extremely common, but premenstrual dysphoric disorder is a distinct, severe, cyclical mood disorder — a formal DSM-5 diagnosis since 2013 — affecting roughly 2 to 5% of menstruating women and carrying a substantially elevated risk of suicidal ideation and attempts. It is defined by timing (luteal-phase mood symptoms that remit after menses) rather than by any abnormal hormone level, and diagnosis requires prospective daily symptom charting over at least two cycles, because retrospective recall markedly over-identifies it and many self-reported cases are actually the premenstrual exacerbation of an underlying depression or anxiety disorder. Treatment is effective: SSRIs are first-line and, distinctively, work with luteal-phase-only dosing as well as continuous dosing; drospirenone-containing combined contraceptives (with a shortened hormone-free interval) help modestly against a large placebo response, and one such pill is specifically approved for PMDD. Cognitive behavioural therapy is reasonable but thinly evidenced. Among supplements, calcium has the most credible randomised support; chasteberry and vitamin B6 rest on low-quality trials, and high-dose B6 risks neuropathy. GnRH agonists and, exceptionally, surgery are reserved for severe treatment-resistant disease. This page addresses cyclical premenstrual disorders specifically; it does not answer general depression, anxiety, or pregnancy queries, which are distinct and separately held or declined.
References & sources
- Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician 2016;94(3):236-240
- Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 2012;169(5):465-475 (PMID 22764360)
- Hantsoo L, Epperson CN. Premenstrual dysphoric disorder: epidemiology and treatment. Curr Psychiatry Rep 2015;17(11):87 (PMID 26377947)
- Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, et al. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry 2017;174(1):51-59 (PMID 27523500)
- Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006;9(1):41-49 (PMID 16172836)
- Prasad D, Wollenhaupt-Aguiar B, Kidd KN, et al. Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: a systematic review and meta-analysis. J Womens Health (Larchmt) 2021;30(12):1693-1707 (PMID 34415776)
- Marjoribanks J, Brown J, O'Brien PMS, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013;6:CD001396 (PMID 23744611)
- Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;2:CD006586 (PMID 22336820)
- Pearce E, Jolly K, Jones LL, et al. Exercise for premenstrual syndrome: a systematic review and meta-analysis of randomised controlled trials. BJGP Open 2020;4(3):bjgpopen20X101032 (PMID 32522750)
- Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 1998;179(2):444-452 (PMID 9731851)
- Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol 2017;217(2):150-166 (PMID 28237870)
- Wyatt KM, Dimmock PW, Jones PW, O'Brien PMS. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999;318(7195):1375-1381 (PMID 10334745)
- Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome (Green-top Guideline No. 48). BJOG 2017;124(3):e73-e105 (PMID 27900828)
- American College of Obstetricians and Gynecologists. Management of premenstrual disorders: ACOG clinical practice guideline. Obstet Gynecol 2023;142(6):1516-1533 (PMID 37973069)
- Lustyk MKB, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health 2009;12(2):85-96 (PMID 19247573)
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback